Renal Cell Cancer (RCC) Disease Forecast and Market Analysis to 2035 - Pipeline, Epidemiology, Treatment & Forecasts Report

Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Renal Cell Cancer (RCC) Disease Forecast and Market Analysis to 2035" report to their offering.

Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms' tumor (nephroblastoma).

The incidence of RCC is higher in those over the age of 60, suggesting that the aging population may play a significant role in current and future disease burden. It is estimated that in 2014 there were 100,290 diagnosed incident cases of RCC in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over the forecast period (2014-34), this is expected to increase to 137,970 cases by 2034, representing an absolute increase of 37.6%.

Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Key Topics Covered:

1. FORECAST: RENAL CELL CANCER
Executive Summary
Market Overview and Trends
Methodology and Market Definition
Afinitor (everolimus)
AGS-003
atezolizumab
Avastin (bevacizumab)
Cometriq (cabozantinib)
Inlyta (axitinib)
Lenvima (lenvatinib)
Nexavar (sorafenib)
Opdivo (nivolumab)
Sutent (sunitinib)
Torisel (temsirolimus)
Votrient (pazopanib)
Primary Research Methodology

2. TREATMENT: RENAL CELL CANCER
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Country Treatment Trees
Current Treatment Options
Prescribing Trends

3. EPIDEMIOLOGY: RENAL CELL CARCINOMA
Executive Summary
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations

4. MARKETED DRUGS: RENAL CELL CANCER
Executive Summary
Product Overview
Product profile: Afinitor
Product profile: Avastin
Product profile: Inlyta
Product profile: Nexavar
Product profile: Opdivo
Product profile: Sutent
Product profile: Torisel
Product profile: Votrient

5. PIPELINE: RENAL CELL CANCER
Executive Summary
Clinical Pipeline Overview
Recently Discontinued Drugs
Target Product Profile
Clinical Trial Design
The Future of Treatment in Renal Cell Cancer
Product profile (late stage): AGS-003
Product profile (late stage): Cometriq
Product profile (late stage): atezolizumab

6. APPENDIX
Appendix: Marketed Drugs: Renal Cell Cancer
Appendix: Pipeline: Renal Cell Cancer

For more information about this report visit http://www.researchandmarkets.com/research/sskp8q/renal_cell_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Kidney Cancer Drugs